Search
site map
IP Handbook Blog
Your source for expert commentary on IP management issues.
Go to the blog
About
MIHR
PIPRA
Fiocruz, Brazil
bioDevelopments- Institute
|
EDWARDS, Mark G
Mark G. Edwards is the Managing Director of Recombinant Capital, Inc. (Recap), a consulting firm based in Walnut Creek, California. More than 500 biotechnology, pharmaceutical, and service companies subscribe to Recap’s databases (Recap.com & rDNA.com) or retain Recap to advise them on biotech alliances and valuations.
Mr. Edwards has been invited to speak to many trade and industry groups about structuring alliances and other business relationships that are related to the development and commercialization of new technologies, compounds, or products. These groups include the Institute of Medicine, the Licensing Executives Society, the Association of University Technology Managers, Sigma Xi (the Scientific Research Society of the National Academy of Sciences), and the Biotechnology Industry Organization. He has also provided expert testimony at deposition or trial in lawsuits dealing with either reasonable royalties or normal custom and practice in the biotechnology and pharmaceutical industries.
Mr. Edwards is on the Board of Directors of Allos Therapeutics, Inc. Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation. He received his B.A. and M.B.A. degrees from Stanford University.
Abstract
Biotechnology and Pharmaceutical Commercialization Alliances: Their Structure and Implications for University Technology Transfer Offices
Abstract:
Understanding biotechnology and pharmaceutical commercialization alliances in the context of several evolving business models has implications for university technology transfer offices (TTOs), as well as for public policy-makers intending to promote biotechnology regionally. This chapter identifies the principal structural and economic elements of biotechnology and pharmaceutical commercialization alliances and the factors that influence partner selection for a particular alliance. The four characteristics of an alliance that generally define the allocation of value between an originator and a commercialization partner include stage of development, product supply, market opportunity, and scope. The chapter explains the types of economic terms typically found in biotechnology alliances and makes an empirical analysis of the economic terms from a sample of biotechnology alliances established between 1981 and 2000. Four specific alliances entered into at different stages of development are detailed as case studies. Several recommendations are provided for university TTOs, along with guidelines for drafting commercialization alliances.
|